Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CXJM-66
- Development stage
- Preclinical
- Lead developer
- Humanwell Healthcare
- Modality
- Small Molecules
- Administration
- Injection
01
Overview
CXJM-66 is a small molecule drug candidate developed by Wuhan Humanwell Hi-Tech Industry, specifically designed for surgical anesthesia and the management of acute pain. It is formulated as an injection and is currently in the preclinical or early stages of development. As part of Humanwell's specialized pipeline in anesthesiology and analgesia, CXJM-66 aims to provide effective perioperative pain control and anesthetic maintenance. While its specific molecular target and mechanism of action have not yet been publicly disclosed, it represents part of the company's effort to expand its portfolio of proprietary anesthetic agents.
- Other names
- CXJM-66注射液及原料药
Beyond the preview
Go deeper on CXJM-66.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CXJM-66.